Wide Ranks

DSGN

Design Therapeutics, Inc.

5.97

Top Statistics
Market Cap 338 M Forward PE -4.92 Revenue Growth 0.00 %
Current Ratio 34.61 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.44 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 254 M Total Cash Per Share 4.49 Total Debt 2 M
Total Debt To Equity 0.9990 Current Ratio 34.61 Book Value Per Share 4.46
All Measures
Short Ratio 1693.00 % Message Board Id finmb_625814292 Shares Short Prior Month 2 M
Return On Equity -0.1778 City Carlsbad Uuid 334bfad0-1826-3cb5-ba7e-3a834e43b6bd
Previous Close 6.15 First Trade Date Epoch Utc 1 B Book Value 4.46
Beta 1.83 Total Debt 2 M Volume 75475
Price To Book 1.34 Fifty Two Week Low 2.17 Total Cash Per Share 4.49
Shares Short Previous Month Date 1 B Target Median Price 5.00 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 7.00 Net Income To Common -47779000
Short Percent Of Float 0.1053 Implied Shares Outstanding 56 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 134060 Average Volume10days 134060
Total Cash 254 M Next Fiscal Year End 1 B Held Percent Insiders 0.3645
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.15 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.54 Open 6.07 Free Cashflow -30067250
State CA Dividend Yield 0.00 % Return On Assets -0.1354
Time Zone Short Name EST Trailing Eps -0.8500 Day Low 5.88
Address1 6005 Hidden Valley Road Shares Outstanding 56 M Price Hint 2
Target High Price 12.00 Website https://www.designtx.com 52 Week Change 1.49
Average Volume 237845 Forward Eps -1.21 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 3434.50 % Is_sp_500 False
Regular Market Day High 6.25 Profit Margins 0.00 % Debt To Equity 0.9990
Fifty Two Week High 7.77 Day High 6.25 Shares Short 2 M
Regular Market Open 6.07 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0475 Operating Cashflow -46043000
Currency USD Time Zone Full Name America/New_York Market Cap 338 M
Is_nasdaq_100 False Zip 92011 Quote Type EQUITY
Industry Biotechnology Long Name Design Therapeutics, Inc. Regular Market Day Low 5.88
Held Percent Institutions 0.5690 Current Price 5.97 Address2 Suite 110
Enterprise To Ebitda -1.44 Financial Currency USD Current Ratio 34.61
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 25 M Two Hundred Day Average 4.35 Enterprise Value 86 M
Forward PE -4.92 Regular Market Volume 75475 Ebitda -60225000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.

Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.